Research programme: antibody therapeutics - BliNK Biomedical SAS
Latest Information Update: 05 Jan 2015
At a glance
- Originator BliNK Biomedical SAS
- Class Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Dec 2014 Preclinical trials in Cancer in France (unspecified route)